C. Guignabert and P. Dorfmuller, Pathology and pathobiology of pulmonary hypertension, Semin Respir Crit Care Med, vol.38, pp.571-584, 2017.

C. Guignabert, L. Tu, B. Girerd, R. N. Huertas, A. Montani et al., New molecular targets of pulmonary vascular remodeling in pulmonary arterial hypertension: Importance of endothelial communication, Chest, vol.147, pp.529-537, 2015.

R. M. Tuder, S. L. Archer, P. Dorfmuller, S. C. Erzurum, C. Guignabert et al., Relevant issues in the pathology and pathobiology of pulmonary hypertension, J Am Coll Cardiol, vol.62, pp.4-12, 2013.

N. Galie, M. Humbert, J. L. Vachiery, S. Gibbs, I. Lang et al., 2015 esc/ers guidelines for the diagnosis and treatment of pulmonary hypertension: The joint task force for the diagnosis and treatment of pulmonary hypertension of the european society of cardiology (esc) and the european respiratory society (ers): Endorsed by: Association for european paediatric and congenital cardiology (aepc), international society for heart and lung transplantation (ishlt), vol.46, pp.903-975, 2015.

A. Boucly, J. Weatherald, L. Savale, X. Jais, V. Cottin et al., Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. The European respiratory journal, p.50, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01757586

Z. Deng, J. H. Morse, S. L. Slager, N. Cuervo, K. J. Moore et al., Familial primary pulmonary hypertension (gene pph1) is caused by mutations in the bone morphogenetic protein receptor-ii gene, American journal of human genetics, vol.67, pp.737-744, 2000.

J. D. Evans, B. Girerd, D. Montani, X. J. Wang, N. Galie et al., Bmpr2 mutations and survival in pulmonary arterial hypertension: An individual participant data meta-analysis, The Lancet. Respiratory medicine, vol.4, pp.129-137, 2016.

K. B. Lane, R. D. Machado, M. W. Pauciulo, J. R. Thomson, J. A. Phillips et al., Heterozygous germline mutations in bmpr2, encoding a tgf-beta receptor, cause familial primary pulmonary hypertension, Nature genetics, vol.26, pp.81-84, 2000.

L. David, C. Mallet, S. Mazerbourg, J. J. Feige, and S. Bailly, Identification of bmp9 and bmp10 as functional activators of the orphan activin receptor-like kinase 1 (alk1) in endothelial cells, Blood, vol.109, pp.1953-1961, 2007.
URL : https://hal.archives-ouvertes.fr/inserm-00376097

M. J. Goumans, A. Zwijsen, P. Ten-dijke, and S. Bailly, Bone morphogenetic proteins in vascular homeostasis and disease, Cold Spring Harb Perspect Biol, p.10, 2018.

C. Guignabert, S. Bailly, and M. Humbert, Restoring bmprii functions in pulmonary arterial hypertension: Opportunities, challenges and limitations, Expert Opin Ther Targets, vol.21, pp.181-190, 2017.

W. Li, R. M. Salmon, H. Jiang, and N. W. Morrell, Regulation of the alk1 ligands, bmp9 and bmp10, Biochem Soc Trans, vol.44, pp.1135-1141, 2016.

L. David, C. Mallet, M. Keramidas, N. Lamande, J. M. Gasc et al., Bone morphogenetic protein-9 is a circulating vascular quiescence factor, Circulation research, vol.102, pp.914-922, 2008.
URL : https://hal.archives-ouvertes.fr/inserm-00277236

G. P. Star, M. Giovinazzo, and D. Langleben, Bone morphogenic protein-9 stimulates endothelin-1 release from human pulmonary microvascular endothelial cells: A potential mechanism for elevated et-1 levels in pulmonary arterial hypertension, Microvasc Res, vol.80, pp.349-354, 2010.

J. E. Park, D. Shao, P. D. Upton, P. Desouza, I. M. Adcock et al., Bmp-9 induced endothelial cell tubule formation and inhibition of migration involves smad1 driven endothelin-1 production, PLoS One, vol.7, p.30075, 2012.

O. Poirier, M. Ciumas, M. Eyries, K. Montagne, S. Nadaud et al., Inhibition of apelin expression by bmp signaling in endothelial cells, American journal of physiology. Cell physiology, vol.303, pp.1139-1145, 2012.

N. Ricard, D. Ciais, S. Levet, M. Subileau, C. Mallet et al., Bmp9 and bmp10 are critical for postnatal retinal vascular remodeling, Blood, vol.119, pp.6162-6171, 2012.

S. Levet, D. Ciais, G. Merdzhanova, C. Mallet, T. A. Zimmers et al., Bone morphogenetic protein 9 (bmp9) controls lymphatic vessel maturation and valve formation, Blood, vol.122, pp.598-607, 2013.

S. Gupta, D. Gill, S. K. Pal, and N. Agarwal, Activin receptor inhibitors--dalantercept, Curr Oncol Rep, vol.17, p.14, 2015.

L. Long, M. L. Ormiston, X. Yang, M. Southwood, S. Graf et al., Selective enhancement of endothelial bmpr-ii with bmp9 reverses pulmonary arterial hypertension, Nature medicine, vol.21, pp.777-785, 2015.

S. Graf, M. Haimel, M. Bleda, C. Hadinnapola, L. Southgate et al., Nat Commun, vol.9, p.1416, 2018.

G. Wang, R. Fan, J. R. Zou, W. Penny, D. J. Varghese et al., Novel homozygous bmp9 nonsense mutation causes pulmonary arterial hypertension: A case report, BMC Pulm Med, vol.16, p.17, 2016.

M. Eyries, D. Montani, S. Nadaud, B. Girerd, M. Levy et al., Widening the landscape of heritable pulmonary hypertension mutations in pediatric and adult cases. The European respiratory journal, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01964973

X. J. Wang, T. Y. Lian, X. Jiang, S. F. Liu, S. Q. Li et al., Germline bmp9 mutation causes idiopathic pulmonary arterial hypertension. The European respiratory journal, 2018.

J. C. Perron and J. Dodd, Actriia and bmprii type ii bmp receptor subunits selectively required for smad4-independent bmp7-evoked chemotaxis, PLoS One, vol.4, p.8198, 2009.

P. B. Yu, H. Beppu, N. Kawai, E. Li, and K. D. Bloch, Bone morphogenetic protein (bmp) type ii receptor deletion reveals bmp ligand-specific gain of signaling in pulmonary artery smooth muscle cells, The Journal of biological chemistry, vol.280, pp.24443-24450, 2005.

O. E. Olsen, M. Sankar, S. Elsaadi, H. Hella, G. Buene et al., Bmpr2 inhibits activin and bmp signaling via wild-type alk2, Journal of cell science, p.131, 2018.

I. Nikolic, L. M. Yung, P. Yang, R. Malhotra, S. D. Paskin-flerlage et al., Bone morphogenetic protein 9 is a mechanistic biomarker of portopulmonary hypertension, American journal of respiratory and critical care medicine, 2018.

S. Srinivasan, M. A. Hanes, T. Dickens, M. E. Porteous, S. P. Oh et al., A mouse model for hereditary hemorrhagic telangiectasia (hht) type 2. Human molecular genetics, vol.12, pp.473-482, 2003.

E. Torsney, R. Charlton, A. G. Diamond, J. Burn, J. V. Soames et al., Mouse model for hereditary hemorrhagic telangiectasia has a generalized vascular abnormality, Circulation, vol.107, pp.1653-1657, 2003.

B. L. Roman, V. N. Pham, N. D. Lawson, M. Kulik, S. Childs et al., Disruption of acvrl1 increases endothelial cell number in zebrafish cranial vessels, Development, vol.129, pp.3009-3019, 2002.

S. Levet, M. Ouarne, D. Ciais, C. Coutton, M. Subileau et al., Bmp9 and bmp10 are necessary for proper closure of the ductus arteriosus, Proc Natl Acad Sci U S A, vol.112, pp.3207-3215, 2015.

G. Simonneau, M. A. Gatzoulis, I. Adatia, D. Celermajer, C. Denton et al., Updated clinical classification of pulmonary hypertension, Journal of the American College of Cardiology, vol.62, pp.34-41, 2013.

G. Telli, B. C. Tel, N. Yersal, P. Korkusuz, and B. Gumusel, Effect of intermedin/adrenomedullin2 on the pulmonary vascular bed in hypoxia-induced pulmonary hypertensive rats, Life Sci, vol.192, pp.62-67, 2018.

T. P. Alastalo, M. Li, P. Vde, J. Pham, D. Sawada et al., Disruption of ppargamma/beta-catenin-mediated regulation of apelin impairs bmp-induced mouse and human pulmonary arterial ec survival, The Journal of clinical investigation, vol.121, pp.3735-3746, 2011.

G. P. Star, M. Giovinazzo, and D. Langleben, Alk2 and bmpr2 knockdown and endothelin-1 production by pulmonary microvascular endothelial cells, Microvasc Res, vol.85, pp.46-53, 2013.

X. Chen, M. Orriols, F. J. Walther, E. H. Laghmani, A. M. Hoogeboom et al., Bone morphogenetic protein 9 protects against neonatal hyperoxia-induced impairment of alveolarization and pulmonary inflammation, Front Physiol, vol.8, p.486, 2017.

C. G. Mitrofan, S. L. Appleby, G. B. Nash, Z. Mallat, E. R. Chilvers et al., Bone morphogenetic protein 9 (bmp9) and bmp10 enhance tumor necrosis factor-alpha-induced monocyte recruitment to the vascular endothelium mainly via activin receptor-like kinase 2, The Journal of biological chemistry, vol.292, pp.13714-13726, 2017.

K. Young, E. Tweedie, B. Conley, J. Ames, M. Fitzsimons et al., Bmp9 crosstalk with the hippo pathway regulates endothelial cell matricellular and chemokine responses, PLoS One, vol.10, p.122892, 2015.

L. Hiress, M. Tu, L. , R. N. Phan, C. Thuillet et al., Proinflammatory signature of the dysfunctional endothelium in pulmonary hypertension. Role of the macrophage migration inhibitory factor/cd74 complex, Am J Respir Crit Care Med, vol.192, pp.983-997, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-02579320

, ? Autosomal dominant mutations in the BMPR2, ACVLR1 (ALK1), GDF2 (BMP9), and in the BMP10 genes predispose to heritable pulmonary arterial hypertension (PAH)

?. Bmp9, BMP10 are two high affinity ligands for ALK1 and BMPRII present in a heterotetrameric complex on pulmonary endothelial cells

, ? Perturbation in the BMP9/BMP10 signaling pathway have emerged as essential in endothelial (dys)function and vascular remodeling